Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.

Rajesh, Y

Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. [electronic resource] - Biochemical pharmacology 06 2019 - 1-16 p. digital

Publication Type: Journal Article

1873-2968

10.1016/j.bcp.2019.03.025 doi


Animals
Antineoplastic Agents, Alkylating--administration & dosage
Base Sequence
Brain Neoplasms--drug therapy
Cell Line, Tumor
Cell Proliferation--drug effects
Dose-Response Relationship, Drug
Drug Delivery Systems--methods
Drug Resistance, Neoplasm--drug effects
Glioblastoma--drug therapy
Humans
Matrix Metalloproteinase 2--genetics
Mice, Nude
NF-E2-Related Factor 2--antagonists & inhibitors
Protein Structure, Tertiary
Temozolomide--administration & dosage
Transcription Factors--antagonists & inhibitors